Advertisement
Advertisement
U.S. Markets close in 6 hrs 22 mins
Advertisement
Advertisement
Advertisement
Advertisement

Applied Genetic Technologies Corporation (AGTC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.4297+0.0013 (+0.30%)
As of 09:36AM EDT. Market open.
Advertisement

Applied Genetic Technologies Corporation

14193 NW 119th Terrace
Suite 10
Alachua, FL 32615
United States
386 462 2204
https://agtc.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees83

Key Executives

NameTitlePayExercisedYear Born
Ms. Susan B. WasherPres, CEO & Director788.55kN/A1961
Mr. Stephen W. PotterVP & Chief Bus. Officer492.17kN/A1956
Dr. Nicholas MuzyczkaCo-FounderN/AN/AN/A
Dr. Barry J. Byrne M.D., Ph.D.Co-FounderN/AN/AN/A
Dr. William W. HauswirthCo-Founder & Member of Ophthalmology Scientific Advisory BoardN/AN/AN/A
Dr. Richard Jude Samulski Ph.D.Co-FounderN/AN/AN/A
Dr. Terence R. Flotte M.D.Co-FounderN/AN/AN/A
Mr. Jonathan I. Lieber M.B.A.Chief Financial OfficerN/AN/A1970
Mr. Gerald Anthony ReynoldsChief Accounting Officer, Principal Accounting Officer & TreasurerN/AN/AN/A
Dr. Abraham Scaria Ph.D.Chief Scientific OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was incorporated in 1999 and is headquartered in Alachua, Florida.

Corporate Governance

Applied Genetic Technologies Corporation’s ISS Governance QualityScore as of July 1, 2022 is 7. The pillar scores are Audit: 6; Board: 6; Shareholder Rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement